A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

Gynecologic Oncology
A ClampG C Jayson

Abstract

There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B). There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Arm A required red cell transfusions while on treatment. Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen.

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Mar 1, 1989·Controlled Clinical Trials·R Simon
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinH E Lambert
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G J RustinH E Lambert
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Apr 2, 1998·Cancer Chemotherapy and Pharmacology·S RomanelliF Zunino
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinP McClean
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR L De Jager
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V BoigeJ P Armand
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E RoyceR Pazdur
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GoreS Z Fields
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Oct 2, 2001·CA: a Cancer Journal for Clinicians·R T GreenleeM Thun
Jun 14, 2002·International Journal of Oncology·A LatorreV Lorusso
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diane C BodurkaDavid M Gershenson
Jan 17, 2003·Journal of the National Cancer Institute·J Baptist TrimbosUNKNOWN European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm

❮ Previous
Next ❯

Citations

Jan 30, 2010·Molecular Pharmaceutics·Vincent J Venditto, Eric E Simanek
May 18, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·R AgarwalS B Kaye
Jun 2, 2005·Critical Reviews in Oncology/hematology·Katsuyuki Hotta, Hiroshi Ueoka
Apr 9, 2005·European Journal of Pharmacology·Miao-Kun Sun, Daniel L Alkon
Mar 12, 2010·The Journal of Continuing Education in the Health Professions·Barbara Campbell
May 13, 2008·Expert Review of Anticancer Therapy·Stephanie L WethingtonThomas J Herzog
Dec 1, 2010·Radiology and Oncology·Lea KnezCatherine Duggan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.